---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-083403"
form_type: "8-K"
ticker: null
cik: "0001305253"
company_name: "Eiger BioPharmaceuticals, Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:23:55.230583+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Eiger BioPharmaceuticals files for Chapter 11; stalking horse sale of Zokinvy for up to $26M

## Summary
- Filed voluntary Chapter 11 petitions on April 1, 2024 in Northern District of Texas.
- Stalking horse APA with Sentynl Therapeutics to buy Zokinvy for up to $26M, subject to court approval and higher bids.
- Patient access to Zokinvy (lonafarnib) to continue uninterrupted during the process.
- Company expects to sell substantially all assets and conduct an orderly wind down.
- Debt accelerated under Innovatus loan due to bankruptcy filing; enforcement stayed by Bankruptcy Code.

## SEC filing metadata
- accession: 0001193125-24-083403
- form_type: 8-K
- cik: 0001305253
- company_name: Eiger BioPharmaceuticals, Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 1.03, 2.04, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1305253/000119312524083403/0001193125-24-083403-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1305253/000119312524083403/d818699d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-083403
- JSON: https://secwatch.observer/filing/0001193125-24-083403.json
- Plain text: https://secwatch.observer/filing/0001193125-24-083403.txt

## Key facts
- Debt Financings
  Eiger BioPharmaceuticals, Inc. reported a default on loan with Innovatus Life Sciences Lending Fund I, LP.
  - Instrument: loan
  - Counterparty: Innovatus Life Sciences Lending Fund I, LP
  - Event: default
  source text: The filing of the Bankruptcy Petitions described in Item 1.03 above constitutes an event of default that accelerated the Company’s obligations under that certain Loan and Security Agreement, dated as of June 1, 2022, by and among Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership, as collateral agent, and the Lenders listed on Schedule 1.1 thereto or otherwise a party thereto from time to time including Innovatus Life Sciences Lending Fund I, LP in its capacity as a Lender, and the Company, EB Pharma, LLC, a Delaware limited liability company and EBPI Merger, Inc., a Delaware corporation (the “ Innovatus Loan ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1305253/000119312524083403/0001193125-24-083403-index.htm
- Distress & Bankruptcy
  Eiger BioPharmaceuticals, Inc. entered chapter 11 in United States Bankruptcy Court for the Northern District of Texas (petition 2024-04-01).
  - Proceeding: chapter 11
  - Court: United States Bankruptcy Court for the Northern District of Texas
  - Petition: 2024-04-01
  source text: On April 1, 2024, Eiger BioPharmaceuticals, Inc. (the “ Company ”) and its direct subsidiaries (together with the Company, the “ Debtors ”) filed voluntary petitions for relief (the “ Bankruptcy Petitions ”) under chapter 11 of Title 11 of the United States Code (the “ Bankruptcy Code ”) in the United States Bankruptcy Court for the Northern District of Texas (the “ Bankruptcy Court ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1305253/000119312524083403/0001193125-24-083403-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.